Prospective study of 9,212 autoimmune rheumatic disease patients showing lower mortality with HCQ, without reaching statistical significance. Authors incorrectly state "HCQ use did not influence occurrence of COVID-19 (RR = 0.909, CI (0.715,1.154), p
= 0.432) or mortality (p
= 0.097)" . CFR for the autoimmune rheumatic disease patients was 4.6 times higher than in the general population from the same area.
Patil et al., 8/24/2021, prospective, India, South Asia, preprint, 20 authors.
risk of death, 65.9% lower, RR 0.34, p = 0.10, treatment 5266, control 3946.
risk of COVID-19 case, 9.1% lower, RR 0.91, p = 0.43, treatment 167 of 5266 (3.2%), control 147 of 3946 (3.7%), adjusted per study.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.